Quviviq (daridorexant) Prescribing Information
Quviviq, with the active ingredient daridorexant, is a medication prescribed for the treatment of insomnia [1]. It works by blocking the activity of orexin neuropeptides, which are involved in regulating wakefulness [1][2].
How does Quviviq work for insomnia?
Daridorexant functions as an orexin receptor antagonist [1]. Orexin is a signaling molecule that promotes wakefulness. By blocking the binding of orexin to its receptors (OX1R and OX2R), daridorexant reduces the wakefulness drive, thus facilitating sleep initiation and maintenance [1][3].
What are the recommended dosages for Quviviq?
The recommended starting dosage for Quviviq is 25 mg taken orally once daily approximately 30 minutes before bedtime [1]. If not sufficiently effective, the dosage can be increased to 50 mg once daily [1]. The maximum recommended dose is 50 mg [1]. It should not be taken if more than 7 hours remain before the planned wake-up time [1].
When can Quviviq be prescribed?
Quviviq is indicated for individuals experiencing difficulty with sleep onset and/or sleep maintenance, which are common symptoms of insomnia disorder [1].
What are the potential side effects of Quviviq?
Common side effects reported with Quviviq include somnolence (daytime drowsiness), headache, and fatigue [1]. Patients are advised to avoid activities requiring mental alertness, such as driving, until they know how Quviviq affects them, as it can cause excessive sleepiness [1].
What are the warnings and precautions associated with Quviviq?
Quviviq carries a boxed warning regarding sleep paralysis and hypnagogic/hypnopompic hallucinations [1]. Patients should be informed of these risks. It is also associated with central nervous system depressant effects and potential for complex sleep behaviors [1]. Caution is advised when co-administered with other CNS depressants. Healthcare providers should assess the risk of suicidal behaviors and ideation [1].
Can Quviviq interact with other medications?
Daridorexant is metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors, such as ketoconazole, can increase daridorexant exposure [1]. Conversely, strong CYP3A4 inducers, like rifampin, can decrease exposure. It is important to inform healthcare providers about all medications, including over-the-counter drugs and supplements, to avoid potential interactions [1].
How does Quviviq's patent status affect its availability?
Information on the specific patent expiration dates for Quviviq (daridorexant) is available through specialized resources. For instance, DrugPatentWatch.com provides detailed information on drug patents and exclusivity periods, which can indicate when generic versions might become available [4].
What clinical trials have been conducted for Quviviq?
Clinical trials for Quviviq involved adult participants diagnosed with insomnia disorder. These studies evaluated the drug's efficacy in improving sleep onset latency and wake after sleep onset, as well as patient-reported outcomes related to sleep quality and daytime function. Key trials demonstrated statistically significant improvements in these measures compared to placebo [1].
---
Sources
1. Quviviq Prescribing Information. Idorsia Pharmaceuticals Ltd.
2. Chong, J., et al. (2023). Daridorexant for the Treatment of Insomnia. The Journal of Pharmacy Technology, 39(2), 79–83.
3. U.S. Food and Drug Administration. (2022, January 7). FDA approves Quviviq (daridorexant-syss) for the treatment of insomnia. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quviviq-daridorexant-syss-treatment-insomnia
4. DrugPatentWatch.com